Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome
Related Experiment Video
Updated: Aug 16, 2026
Detection of SARS-CoV-2 Receptor-Binding Domain Antibody using a HiBiT-Based Bioreporter
Published on: August 12, 2021
Nelson Lee1, P K S Chan, Margaret Ip
1Department of Medicine and Therapeutics, Prince of Wales Hospital, Faculty of Medicine, The Chinese University of Hong Kong, 30-32 Ngan Shing Street, Shatin, NT, Hong Kong, PR China.
Background:
The association between a robust or depressed antibody response and clinical severity of SARS remains unknown.
Objectives:
To study seroconversion and the magnitude of IgG responses in a SARS cohort with different disease severities.
Study Design And Method:
A retrospective analysis of all acute and convalescent-phase sera collected from a cohort of laboratory-confirmed SARS cases. Anti-SARS-CoV IgG antibody was detected using indirect immunofluorescence technique and quantified by two-fold serial dilutions. Characteristics of patients who seroconverted "early" (
Results:
A total of 325 laboratory-confirmed SARS cases were analyzed; of which 301 (92.6%) had anti-SARS-CoV IgG detected in their sera at the time of sampling. IgG was first detected on day 4 of illness; seroconversion occurred at a median of 16 days (range 4-35 days), and IgG peak levels were reached in the fourth week. Early seroconversion (
Conclusions:
Severe SARS is associated with a more robust IgG response.
More Related Videos
10:25Detection of SARS-CoV-2 Neutralizing Antibodies using High-Throughput Fluorescent Imaging of Pseudovirus Infection
Published on: June 5, 2021
07:08A Rapid, Multiplex Dual Reporter IgG and IgM SARS-CoV-2 Neutralization Assay for a Multiplexed Bead-Based Flow Analysis System
Published on: April 6, 2021
Related Concept Videos
01:29Coronavirus
01:29Respiratory Syncytial Virus Disease